Such kinds of global approaches, compiled with other high throughput and next-generation sequencing analyses (e.g., DNase-Seq, SELEX-seq, ChIA-Pet, 4C-seq, cleavage under targets and release using nuclease (CUT&RUN) analyses, methylome, ATAC-seq, and binding energy topography by sequencing (BET-seq), etc.)would also provide opportunities to identify critical downstream factors as new potential targets in AML and other cancers associated with HOXA9 over-expression. The gene discussed is HOXA9; the disease is acute myeloid leukemia.